These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. Sinik Z; Alkibay T; Ataoglu O; Biri H; Sözen S; Deniz N; Karaoglan U; Bozkirli I Int J Urol; 1997 Nov; 4(6):546-51. PubMed ID: 9477181 [TBL] [Abstract][Full Text] [Related]
3. Altered patterns of MDM2 and TP53 expression in human bladder cancer. Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890 [TBL] [Abstract][Full Text] [Related]
4. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Esrig D; Spruck CH; Nichols PW; Chaiwun B; Steven K; Groshen S; Chen SC; Skinner DG; Jones PA; Cote RJ Am J Pathol; 1993 Nov; 143(5):1389-97. PubMed ID: 7901994 [TBL] [Abstract][Full Text] [Related]
5. The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder. Alexander RE; Williamson SR; Richey J; Lopez-Beltran A; Montironi R; Davidson DD; Idrees MT; Jones CL; Zhang S; Wang L; Rao Q; Pedrosa JA; Kaimakliotis HZ; Monn MF; Koch MO; Cheng L PLoS One; 2014; 9(4):e95724. PubMed ID: 24752337 [TBL] [Abstract][Full Text] [Related]
6. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332 [TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. Ecke TH; Lenk SV; Schlechte HH; Loening SA Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330 [TBL] [Abstract][Full Text] [Related]
8. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma. Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186 [TBL] [Abstract][Full Text] [Related]
9. [Molecular biology in bladder carcinoma: contributions of immunohistochemistry]. Ferrari P; Trentini GP; De Gaetani C; Caragnani L; Righi E; Ferrari G Arch Ital Urol Androl; 1997 Sep; 69(4):271-7. PubMed ID: 9417298 [TBL] [Abstract][Full Text] [Related]
10. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Simon R; Eltze E; Schäfer KL; Bürger H; Semjonow A; Hertle L; Dockhorn-Dworniczak B; Terpe HJ; Böcker W Cancer Res; 2001 Jan; 61(1):355-62. PubMed ID: 11196186 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Dekairelle AF; Tombal B; Cosyns JP; Gala JL Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567 [TBL] [Abstract][Full Text] [Related]
12. Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas. Itoi T; Watanabe H; Yoshida M; Ajioka Y; Nishikura K; Saito T Pathol Int; 1997 Aug; 47(8):525-30. PubMed ID: 9293532 [TBL] [Abstract][Full Text] [Related]
13. p53 protein expression and proliferative activity in imprints of superficial transitional cell carcinoma of the bladder. Ioakim-Liossi A; Pantazopoulos D; Karakitsos P; Athanassiadou P; Aroni K; Giahnaki AE; Athanassiades P Anal Quant Cytol Histol; 2000 Jun; 22(3):223-8. PubMed ID: 10872039 [TBL] [Abstract][Full Text] [Related]
14. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma. Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850 [TBL] [Abstract][Full Text] [Related]
15. p53 mutations in bladder carcinoma cell lines. Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250 [TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438 [TBL] [Abstract][Full Text] [Related]